Prof Perry presents at ASCO 2016, a Canadian-led randomised phase III trial found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%.

Read the news story or watch the video interview for more.